MCRB vs DBVT vs REGN vs ABBV vs MRK

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Seres Therapeutics, Inc. (MCRB) offers the better valuation at 12. 1x trailing P/E, making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Seres Therapeutics, Inc.

(MCRB) is the cheapest at 12. 1x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Merck & Co. , Inc. wins at 1. 03x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a reasonable growth-adjusted valuation.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -98. 1% for Seres Therapeutics, Inc. (MCRB). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus MCRB's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Seres Therapeutics, Inc. 's 1. 69β — meaning MCRB is approximately 400% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc. grew EPS 103. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Merck & Co. , Inc. (MRK) is the more undervalued stock at a PEG of 1. 03x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, AbbVie Inc. (ABBV) trades at 14. 3x forward P/E versus 21. 9x for Merck & Co. , Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, ABBV (3.

2% yield), MRK (2. 9% yield), REGN (0. 5% yield) pay a dividend. MCRB, DBVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Seres Therapeutics, Inc. (MCRB) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, MCRB: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MCRB is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; REGN is a mid-cap deep-value stock; ABBV is a large-cap income-oriented stock; MRK is a large-cap deep-value stock. ABBV, MRK pay a dividend while MCRB, DBVT, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.